OLMA OLEMA PHARMACEUTICALS INC Operational Disruptions 8-K Filing 2023 - Phase 2 Clinical Study Results Olema Pharmaceuticals announced results from a Phase 2 clinical study of palazestrant for the treatment of metastatic ER+/HER2- breast cancer.Get access to all SEC 8-K filings of the OLEMA PHARMACEUTICALS INC